Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;32(2):551-7.
doi: 10.1007/s00345-013-1191-3. Epub 2013 Nov 7.

Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma

Olivier Cussenot  1 , Karim Sighar, Mansoor Mohammed, Sylvain Hugonin, Valérie Ondet, Stéphane Larre, Roger Lacave, Morgan Roupret, Géraldine Cancel-Tassin
Affiliations

Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma

Olivier Cussenot et al. World J Urol. 2014 Apr.

Abstract

Introduction: Bladder carcinoma (B-TCC) is the fifth most prevalent carcinoma in the United States (US) or Europe. In addition, B-TCC is the most expensive carcinoma per patient between diagnosis and death, because of its 50-80 % recurrence rate. B-TCC is an optimal carcinoma for which to detect DNA alterations in urine, which is easily obtainable. Chromosomal aberrations in tumors have been closely related to the carcinogenesis process.

Material and methods: We developed a highly specific and sensitive oligo-CGH-array for the diagnosis and follow-up of B-TCC, based on the detection of chromosomal aberrations in urine samples. One hundred and sixty-four urine samples were analyzed. The qualitative results, including chromosomal aberrations, were obtained. Quantitative results are expressed as a percentage of chromosomal alterations on the autosomes.

Results: From the urine samples, we were able to differentiate B-TCC from non-malignant conditions with an accuracy of 100 % for patients without history of B-TCC. For follow-up of B-TCC in clinical practice, at least a deletion (8p; 9p; 9q) or a cut-off of >2 % of chromosomal imbalance was considered as a positive test. According to our criteria, 100 % of high-grade tumors were diagnosed, and the sensitivity to predict positive cystoscopy was 95 % (specificity 73 %). A cut-off >9 % was a strong signature of high-grade TCC (odds ratio 53 CI 95 % 7-417; p = 0.0002).

Conclusion: We developed a sensitive clinical tool for the detection of B-TCC using DNA extracted from patient urine. This tool is also able to identify low-grade B-TCC and identify high-risk patients harboring a high-grade disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Examples of normal profiles on chromosome 1, a gain on the 8q chromosome arm and a deletion on the 9p chromosome arm at the 9p21 locus
Fig. 2
Fig. 2
Synoptic table of chromosomal arms by aberrations according to the 2004 WHO aggressiveness classification of non-muscle-invasive B-TCC. PUNLMP papillary urothelial neoplasm of low malignant potential, LGPC and HGPC low-grade and high-grade papillary carcinoma
See this image and copyright information in PMC

References

    1. Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. BJU Int. 2013;111(3 Pt B):78–84. doi: 10.1111/j.1464-410X.2012.11454.x. - DOI - PubMed
    1. Schäfauer C, Ettori D, Rouprêt M, Phé V, Tualle JM, Tinet E, Avrillier S, Egrot C, Traxer O, Cussenot O. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. J Urol. 2013;190(1):271–277. doi: 10.1016/j.juro.2013.01.100. - DOI - PubMed
    1. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, Riedl C, Bugelnig J, Hobisch A, Burger M, Mikuz G, Pichlmeier U. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : a multicenter randomized, double-blind, placebo-controlled trial. Cancer. 2011;117(5):938–947. doi: 10.1002/cncr.25523. - DOI - PubMed
    1. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95:588. doi: 10.1093/jnci/95.8.588. - DOI - PubMed
    1. Zhang Y, Denton BT, Nielsen ME. Comparison of surveillance strategies for low-risk bladder cancer patients. Med Decis Mak. 2013;33(2):198–214. doi: 10.1177/0272989X12465353. - DOI - PubMed

Substances

LinkOut - more resources